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Abstract
BACKGROUND: Aim of the study was to evaluate the diagnostic performance of FDG PET-CT for the detection of local and 
distant disease relapse in surgically treated patients with renal cell carcinoma (RCC).
MATERIAL AND METHODS: This retrospective study includes 96 patients underwent FDG PET-CT scanning in the post-sur-
gical follow up within the first 6–12 months referred to nuclear medicine department, to perform PET/CT study. Each patient 
underwent FDG PET-CT with low dose CT, followed immediately by full dose Ce-CT. Sites of the relapse were categorized into 
local and distant recurrence. Distant recurrence sites were divided into lymph nodes, lung, bone, and other soft tissue sites. 
The final diagnosis of disease status was made on subsequent follow up by conventional imaging (CT/MRI), FDG PET-CT, or 
histopathology whenever possible.
RESULTS: Local and/or distant disease relapse was confirmed in 69 (71.9%) patients and the rest 28.1% were free. Regarding 
local recurrence FDG PET-CT showed specificity of 100% compared to 98.6% with Ce-CT (p > 0.05) and higher sensitivity noted 
with Ce-CT (100%) compared to 96% with FDG PET-CT. For global distant sites of metastases Ce-CT revealed high sensitivity 
and NPV of 93.3% & 96.9% respectively yet lower specificity (93.96%) and PPV (87.5%) was seen with Ce-CT compared to 
99.6% and 99.1% with FDG PET-CT respectively. The higher Ce-CT sensitivity was attributed to its ability to detected 100% of 
cases of lung metastases compared to 80.6% with FDG PET-CT (P-value < 0.05).
CONCLUSION: FDG PET-CT appears to be a very efficient tool in post-surgical surveillance of patients with RCC with notable 
ability to probe even uncommon sites of distant recurrence.
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Nucl Med Rev 2018; 21, 2: 85–91
partial or total nephrectomy) remains the mainstay of localized di-
sease treatment [2]. Surgically treated localized disease has favora-
ble outcome with 5 years survival rate of 68.4%; however, 20–40% 
of patients developed local or distant disease relapse, lowering 
survival rate to less than 10% [3]. Moreover, recently, the oncogenic 
mechanism of RCC has been elucidated and drugs that target 
relevant biological pathways have been developed as sunitinib, 
sorafenib, multiple tyrosine kinase inhibitors (multiple TKIs) targeting 
vascular endothelial growth factor receptor (VEGFR), and everoli-
mus [4, 5]. Therefore, postoperative planning and follow up in RCC 
are worthwhile with continuous evolution of recommendations for 
Introduction
Renal cell carcinoma (RCC) is the most common type of kidney 
cancer in adults, responsible for approximately 90–95% of cases, 
and represents 3% of all adult cancers [1]. It has been known for 
its resistant nature to chemo and radiotherapies, thus surgery (either 
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surveillance of patients with RCC [2]. The morphological diagnostic 
modalities Ultrasonography (US), contrast enhanced computed 
tomography (Ce-CT) and magnetic resonance imaging (MRI) 
are commonly used imaging modalities for the detection of RCC 
recurrences, however, a consensus surveillance protocol does not 
exist for follow-up of RCC after nephrectomy [2, 6]. RCC has been 
shown to metastasize to almost all soft tissues in the body, but 
most commonly to the lung, followed by bone, liver, brain, and lo-
cal recurrence. Metastases to brain, bone, and liver often present 
as widely disseminated disease. Modalities of the survey are chosen 
to reflect the most prevalent locations of RCC recurrence. In ad-
dition, stringent surveillance to detect recurrences in areas most 
amenable to further therapy is paramount [7].
Although the role of FDG PET-CT in characterizing renal 
masses and diagnosing RCC is conflicting, the aggressive and 
often insidious nature of RCC reflected by its high recurrence 
rates can be probed by FDG PET-CT with its known ability to 
detect actively proliferating or aggressive disease in one setting 
whole body imaging [8]. Therefore, the aim of our study was to 
investigate the role of FDG PET-CT in the detection of local and 
distant disease relapse in patients who underwent nephrectomy 
for RCC in comparison to one of the traditional standard tech-
niques which are (Ce-CT).
Material and methods
This retrospective study was conducted on 96 patients with 
RCC all pathologically confirmed after nephrectomy. The major-
ity (78%) was of clear cell subtype, the remaining (22%) were of 
chromophobe and papillary cell subtypes. Patients were referred 
to the nuclear medicine unit in National Cancer Institute (NCI) and 
Children Cancer Hospital (CCH) to perform FDG PET-CT study, due 
to clinical suspicion of disease relapse, from 3rd February 2010 to 
31st December 2015. Each patient underwent FDG PET-CT with low 
dose CT followed by a full dose Ce-CT study. 
Inclusion criteria
 — Patients with histologically proven renal cell carcinoma after 
surgical resection.
 — Patients underwent FDG PET-CT scanning in the post-surgical 
follow up within the first 6–12 months after surgery to exclude 
(or confirm) local or distant disease relapse. 
FDG PET-CT findings verified by histology and/or other imaging 
magnetic resonance imaging [MRI], or bone scan performed within 
a period of 1 month.
Availability of clinical follow-up data including multidisciplinary 
meeting reports, laboratory exams, and radiological exams as ul-
trasound examinations, ce-CT, MRI, FDG PET-CT, and bone scans, 
available for at least 6 months from the date of the first post-surgical 
FDG PET scan.
FDG PET-CT scans were retrospectively retrieved and re-
viewed by a nuclear medicine physician and correlated with ce-CT 
scans that were reviewed by radiodiagnosis physician.
PET-CT findings were interpreted as positive if the focal area 
of FDG uptake in the abdomen or outside the abdomen was more 
than the surrounding background tissue.
Ce-CT considered positive: in case of soft tissue lesions (local 
or distant); the presence of sizable lesions, the pattern of contrast 
enhancement, reaching a pathological size (as in case of nodal 
involvement). In case of bone lesions; the presence of lytic or 
sclerotic changes.
The reference for results verification was based on:
 — Histo-pathological data (if available)
 — Clinico-laboratory assessment and follow-up data: were, other-
wise, the reference.
FDG PET-CT scanning and image analysis
FDG PET-CT study was performed using a dedicated PET-CT 
scanner. This camera integrates a PET scanner with a dual-section 
helical CT scanner and allows the acquisition of co-registered 
CT and PET images in one session. All patients fasted for 
6 hours before the injection of 370 MBq of 18 F-FDG. Scanning 
started 60 minutes after tracer injection (5–7 bed positions; acqui-
sition time, 2–3 min/bed position). Blood glucose levels did not 
exceed 150 mg/dL. Initially, patients were examined in the supine 
position with arms elevated, and CT scanning was started at the 
level of skull base with the following parameters: 40 mAs; 130 kV; 
slice thickness, 2.5 mm; pitch, 1.5. The CT scans were acquired 
during shallow normal breathing and reached caudally to the mid 
thighs. PET over the same region was performed immediately af-
ter acquisition of the low dose CT images. CT-data were used for 
attenuation correction, and images were reconstructed as 3-mm 
slices applying a standard iterative algorithm (ordered-subset 
expectation maximization). Images were interpreted at a work-
station equipped with fusion software that provides multi-planar 
reformatted images and enables display of the PET images, CT 
images, and fused PET-CT images in any percentage relation. 
Image interpretation was accomplished by two experienced nuclear 
medicine physicians and a radiologist. The analysis was performed 
using a multimodality computer platform. For semi-quantitative 
analysis, the nuclear medicine physicians referred to the PET-CT 
fusion images to set a spherical volume of interest (VOI) over the 
regions of interest and then recorded the maximum standardized 
uptake value (SUV max) in the VOI. 
Contrast-enhanced CT scanning 
CT scanning was performed using multi-detector CT scanner. 
Non-ionic iodinated contrast material (300 mgI/ml) at 2.0 ml per 
kilogram body weight was injected through antecubital vein with 
a total injection time of 30 seconds in principle via automated injec-
tor (based on the recent available kidney function tests).
Statistical analysis 
All data were analyzed using SPSS 22.0 for Windows (SPSS 
Inc., Chicago, IL, USA) and MedCalc 13 for windows (MedCalc 
Software bvba, Ostend, Belgium). The trend of change in percent 
of ordinal categorical variables was compared using Chi-square 
test for trend. McNemar’s test was used for comparison between 
paired data. The sensitivities, specificities, positive predictive va-
lues (PPV), negative predictive values (NPV), and accuracies were 
calculated. All tests were two-sided with p < 0.05 was considered 
statistically significant. 
Written consents were routinely obtained from patients before 
studies and the local ethics committee has approved the evaluation 
of retrospectively collected patients’ data.
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Table 1. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of local tumor recurrence in patients with surgically treated 
RCC. (No. of patients = 96)
FDG PET-CT Ce-CT
TP 24 25
TN 71 70
FP 0 1
FN 1 0
SN 96% 100%
SP 100% 98.6%
NPV 98.6% 100%
PPV 100% 96.15%
Accuracy 98.95% 98.95%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive 
value
Results
96 FDG PET-CT scans for 96 patients with pathologically proved 
RCC were retrospectively reviewed and analyzed. As regards the 
patients characteristics; males represented 65%, among our group 
and age group ranged from 37 to 70 years. 
All available follow up data including blood tests, imaging, and 
biopsy results (when available) were used to confirm presence or 
absence of disease relapse as well as for monitoring therapy re-
sponse. Accordingly, local and/or distant disease relapse was con-
firmed in 69 (71.9%) patients and the remaining 28.1% were totally 
free. Sites of the relapse were classified into 5 groups: local tumor 
Figure 2. 38-years-old male patient underwent left nephrectomy for 
RCC, FDG PET-CT revealed FDG avid recurrent soft tissue mass at 
the operative bed SUVmax ~12.2. as well as large peritoneal deposit 
SUVmax ~10.2
Figure 1. 56-years-old male patient with RCC underwent left nephrectomy with suspected recurrence, FDG PET-CT showed active mass infiltrating 
the left psoas muscle with SUVmax ~6.5, lumbar peritoneal nodule with SUVmax ~4.5 and common iliac nodal deposits with SUVmax ~9.5
site, lymph nodes, lung, bone, and other soft tissue sites (brain, 
liver, adrenal, subcutaneous, intramuscular, and pancreas).
As regards Local recurrence detection patient based 
analysis for both FDG PET-CT & Ce-CT were performed. There 
is an overall comparable result with the same accuracy (98.95%) 
and higher sensitivity noted with Ce-CT (100%) compared to 96% 
with FDG PET-CT. Meanwhile, FDG PET-CT was able to exclude 
local tumor recurrence in one patient increasing its specificity to 
100% compared to 98.6% with Ce-CT (p > 0.05) (Table 1, Fig. 1 
and 2). 
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Of the 96 studied patients, 63 had distant metastases with total 
number of 120 true positive sites of metastases, thus site based 
analysis was performed and higher incidence of false positive in-
stances with distant metastases were reported in 16 patients with 
Ce-CT lowering its specificity (93.96%) and PPV (87.5%) compared 
to single false positive instance for FDG PET-CT with specificity and 
PPV of 99.6% and 99.1% respectively (p-value < 0.05). 
On the other hand, slightly higher (yet still comparable) sen-
sitivity and NPV shown by Ce-CT representing 93.3% and 96.9% 
respectively as compared to PET with sensitivity and NPV of 92.5% 
and 96.7% respectively. An overall higher diagnostic accuracy 
was revealed by PET/CT (97.4%) compared to Ce-CT (94%) yet 
no statistically significant difference (Table 2).
Furthermore, sites of distant metastases were classified 
as 4 main regions: lymph nodes, lung, bone, and other soft tissue 
sites (brain, liver, adrenal, subcutaneous, intramuscular, & pan-
creas). The analysis was performed comparing the diagnostic 
performance of both modalities at these different regions of distant 
metastases.
In our study 40 patients reveal true regional and/or distant 
nodal metastases, confirmed on follow up and/or histopathology, 
FDG PET-CT was able to detect nodal deposits with a sensitivity of 
100% compared to 3 missed cases with Ce-CT with a sensitivity of 
92.5%. Single false positive case reported with FDG PET-CT proved 
on histopathology to be reactive in nature (with specificity & PPV 
of 98.2% & 97.6% respectively), Meanwhile, considering size the 
determinant factor for CT interpretation, 3 cases were false positive 
by reaching pathological size on CT and proved to be of benign 
nature on follow up, lowering its specificity indices (Specificity & 
PPV) to 92.9 and 90.2% respectively. Higher overall diagnostic ac-
curacy was observed with FDG PET-CT of 99% compared to 92.7% 
with Ce-CT (Table 3). It is worthwhile to note that true PET positive 
nodal cases showed wide range of variable degrees of metabolic 
activity with SUV max ranged from 1.7 to 20.3 (with mean value of 
7.82), those active lesions also were of different sizes from 1 to 11.6 
cm (positivity was not limited to pathological size).
Regarding lung metastases, as expected, full dose Ce-CT 
didn’t miss a case with sensitivity of 100% compared to 80.6% for 
FDG PET-CT, which was statistically significant (P-value < 0.05). 
The cases that were truly positive on CT and missed by PET 
were ≤ 12 mm in diameter. On the contrary, FDG PET-CT showed 
higher specificity, with all the detected cases truly positive and the 
average value for SUV max was 4.68, with specificity and PPV 100% 
compared to specificity & PPV of 93.8 & 88.6% with Ce-CT (Table 4).
FDG PET-CT showed optimum performance in both sensiti-
vity and specificity indices reaching 100% in detection of bone 
metastases with SUV max ranged from 2 to 11.9 (average SUV 
max 4.6), whereas lower indices were noted with CT especially the 
PPV that was 87.5% with Ce-CT compared to 100% with PET/CT 
(p-value < 0.05) (Table 5, Fig. 3).
In our study, other soft tissue sites including the brain, liver, 
adrenal, subcutaneous, intramuscular, and pancreas were de-
tected in 34 patients of the 96 patients. Higher diagnostic perfor-
mance revealed by PET/CT with sensitivity, specificity, NPV, & PPV 
repre senting 91.2%, 100%, 95.4%, 100% and 96.9% respectively 
compared to 88.2%, 90.5%, 93.4% ,83.3% and 90.6% with Ce-CT, 
with statistical significance shown in PPV (P-value < 0.05) (Table 6, 
Fig. 4), The average value for SUV max was 7.15.
Discussion
RCC represents about 3% of adult malignancies. It is known for 
its variable natural history. Approximately 30% of case are metastatic 
Table 2. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of distant metastases in patients with surgically treated RCC. 
(No. of true metastatic sites = 120)
FDG PET-CT Ce-CT
TP 111 112
TN 263 249
FP 1 16
FN 9 8
SN 92.5% 93.3%
SP 99.6% 93.96%
NPV 96.7% 96.9%
PPV 99.1% 87.5%
Accuracy 97.4% 93.8%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive 
value
Table 3. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of Nodal metastases in patients with surgically treated RCC. 
(No. of patients = 96)
FDG PET-CT Ce-CT
TP 40 37
TN 55 52
FP 1 4
FN 0 3
SN 100% 92.5%
SP 98.2% 92.9%
NPV 100% 94.5%
PPV 97.6% 90.2%
Accuracy 99% 92.7%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive value
Table 4. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of Lung metastases in patients with surgically treated RCC. 
(No. of patients = 96)
FDG PET-CT Ce-CT
TP 25 31
TN 65 61
FP 0 4
FN 6 0
SN 80.6% 100%
SP 100% 93.8%
NPV 91.5% 100%
PPV 100% 88.6%
Accuracy 93.8% 95.8%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive 
value
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at the time of diagnosis and 20 to 40% develop metastases after 
radical nephrectomy [1, 3].
Disease recurrence, whether after partial or radical nephrectomy 
could be assessed by clinical suspicion and surveillance imaging. 
With the development of anti-angiogenesis targeted therapies, early 
detection of recurrence and proper disease surveillance become of 
Table 6. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of Soft Tissue metastases in patients with surgically treated 
RCC. (No. of patients = 96)
FDG PET-CT Ce-CT
TP 31 30
TN 62 57
FP 0 6
FN 3 4
SN 91.2% 88.2%
SP 100% 90.5%
NPV 95.4% 93.4%
PPV 100% 83.3%
Accuracy 96.9% 90.6%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive 
value
Table 5. Diagnostic performance of FDG PET-CT versus Ce-CT in 
detection of Bone metastases in patients with surgically treated RCC. 
(No. of patients = 96)
FDG PET-CT Ce-CT
TP 15 14
TN 81 79
FP 0 2
FN 0 1
SN 100% 93.3%
SP 100% 97.5%
NPV 100% 98.8%
PPV 100% 87.5%
Accuracy 100% 96.9%
TP — true positive, TN — true negative, FP — false positive, FN — false negative, SN — 
sensitivity, SP — specificity, NPV — negative predictive value, PPV — positive predictive 
value
Figure 3. 68-years-old male patient underwent restaging FDG PET-CT, 
which revealed FDG avid metabolically active local tumor recurrence 
associated with FDG avid multiple nodal, hepatic, subcutaneous 
nodules, bilateral pulmonary nodules, and widespread bone/ bone 
marrow deposits. First raw images could represent the absence of 
textural bone changes on CT images that appeared definitely infiltrated 
on PET images. Rest of images showed bilateral supraclavicular 
nodal involvement, active small right anterior chest wall nodule (easily 
missed on CT scanning alone), and active liver deposit
Figure 4. 62-years-old male patient underwent right radical 
nephrectomy and referred on clinical suspicion for recurrence. Images 
revealed metabolically active right infra-spinatus intramuscular lesion 
(1st raw) and right chest wall subcutaneous soft tissue nodule (2nd raw) 
with SUV max 6.5, multiple FDG avid destructive rib lesions associated 
with soft tissue component and NON-FDG avid lung nodules largest at 
right lower lobe (illustrated at the 3rd raw images) measuring 1.2 cm
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great interest [9, 10]. Up till now, no consensus has been reached 
for the pattern of follow up or disease surveillance and several 
authors have emphasized the need to individualize surveillance 
based on tumour stage, grade, tumour volume and type of surgery, 
whether partial or total nephrectomy [11]. 
Local recurrence after nephrectomy for RCC is uncommon. The 
prevalence has been reported to range between 1 and 2% in diffe-
rent series. Recurrent RCC after RN may be a result of metastatic 
disease within the ipsilateral adrenal gland, which was left in situ 
at the time of the primary surgery, inadequate excision of regional 
lymph nodes, or recurrent/residual disease in perirenal fatty tissue, 
in renal fossa, or within the psoas muscle. Inadvertent perioperative 
tumoral implantation may be another reason [12–14].
In the current study, comparable high diagnostic accuracy 
(98.95%) was noted with FDG PET-CT and Ce-CT, and FDG PET-CT 
was able to exclude local tumor recurrence in one patient increasing 
its specificity to 100% compared to 98.6% with Ce-CT (p > 0.05). 
Kumar et al. studied 63 patients who underwent 103 FDG PET-CT 
scans for evaluation of postsurgical RCC recurrence and reported 
sensitivity, specificity, and accuracy of 90%, 91%, and 90%, respec-
tively [15]. Lower sensitivity (82%) and similar specificity (100%) 
was reported by Bertagna et al. [16], while lower sensitivity and 
specificity were reported by Alongi P et al., in a study done for the 
clinical role of FDG PET-CT in the restaging of RCC. For recurrent 
and/or metastatic lesions in 104 patients, FDG PET-CT demon-
strated sensitivity and specificity of 74 and 80%, respectively [17]. 
In our study, Ce-CT revealed high sensitivity indices (93.3% and 
96.9% for sensitivity and NPV respectively) but with high incidence 
of false positive instances with distant metastases reported in 16 
patients lowering its specificity (93.96%) and PPV (87.5%) compared 
to single false positive instance for FDG PET-CT with specificity 
and PPV of 99.6% & 99.1% respectively (p-value < 0.05). Though 
other studies demonstrated variable FDG PET-CT sensitivity for 
detection of distant metastases (ranged from 63.6 to 90%, almost 
all illustrated specificity from 91 to 100%. Also, the additional infor-
mation obtained from FDG PET influenced the course of therapeutic 
management in 11% of cases [18–21].
In our study, FDG PET-CT was able to detect nodal deposits with 
sensitivity of 100% compared to 92.5% with ce-CT. For CT, positivity 
is size dependent and reaching the pathological size stands be-
hind the false positive cases and the relatively lower specificity 
of 92.9% as compared to FDG PET (98.2%). True PET positive 
nodal cases showed variability in metabolic activity with SUV max 
ranged from 1.7 to 20.3 (with a mean value of 7.82). Those active 
lesions ranged in size from 1 to 11.6 cm (positivity was not limited 
to pathological size). Other retrospective analysis by Win et al, 
reviewed the FDG PET-CT studies in 315 RCC patients with biopsy 
results. FDG PET-CT studies exhibited 100% sensitivity and 100% 
specificity in detecting all metastatic lesions of RCC, the smallest 
of which detected was a 7-mm lymph node [22].
Ce-CT optimum sensitivity for detection of lung metasta-
ses is well established. In our study reached 100% compared 
to 80.6% for FDG PET-CT which was statistically significant 
(P-value < 0.05). The cases that were truly positive on CT and 
missed by PET were ≤ 12 mm in diameter. However, the upper 
hand for specificity is still in favour of FDG PET-CT as all the de-
tected cases were truly positive with the average value for SUV max 
was 4.68. In another study, Antonija et al. reported that the accuracy 
of FDG PET-CT in metabolically active metastases is generally 
higher when compared to conventional CT except for identifying 
small lung deposits [23].
FDG PET-CT showed optimum performance with both sensi-
tivity and specificity indices reaching 100% in detection of bone 
metastases with SUV max ranged from 2 to 11.9 (average SUV max 
4.6), whereas lower indices were noted with CT, especially the PPV 
that was 87.5% with Ce-CT compared to 100% with FDG PET-CT 
(p-value < 0.05). This is comparable to the study done by Sharma 
et al; that concluded that FDG PET-CT showed similar accuracy for 
visualization of bone metastasis 93.7% [24].
Higher sensitivity and specificity indices were noted with FDG 
PET-CT with sensitivity, specificity, NPV, & PPV representing 91.2%, 
100%, 95.4%, 100% and 96.9% respectively compared to 88.2%, 
90.5%, 93.4%, 83.3% & 90.6% with Ce-CT. The false positive 
cases with CT were attributed to sizable adrenal nodules, however, 
MRI and follow up revealed their benign (adenomatous) nature, 
also small equivocal liver lesions that serial scans and follow-up 
reassure their stability over time and benign etiology. Regarding the 
CT false negative results, three out of the four cases had missed 
intramuscular involvement at different muscles groups and the 
fourth had few small subcutaneous nodules. All were obvious in 
PET images and one of the subcutaneous nodules was biopsied 
and its metastatic nature was histologically proven. 
Conclusions
FDG PET-CT appears to be a very efficient tool in post-surgical 
surveillance of patients with RCC with notable ability to probe even 
uncommon sites of distant recurrence encouraging its introduc-
tion (together with complementary dedicated CT lung scanning 
protocol) to the follow-up protocol of post-surgically treated RCC 
patients. Meanwhile further larger scale studies with periodic follow 
up is recommended to support this role and to illustrate the optimum 
timing and frequency of FDG PET-CT imaging during follow up.
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